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Fgf8 and Tbx1 have been shown to interact in patterning the aortic arch, and both genes are required in formation and growth of the outflow
tract of the heart. However, the nature of the interaction of the two genes is unclear. We have utilized a novel Tbx1Fgf8 allele which drives Fgf8
expression in Tbx1-positive cells and an inducible Cre-LoxP recombination system to address the role of Fgf8 in Tbx1 positive cells in modulating
cardiovascular development. Results support a requirement of Fgf8 in Tbx1 expressing cells to finely control patterning of the aortic arch and great
arteries specifically during the pharyngeal arch artery remodeling process and indicate that the endoderm is the most likely site of this interaction.
Furthermore, our data suggest that Fgf8 and Tbx1 play independent roles in regulating outflow tract development. This finding is clinically
relevant since TBX1 is the candidate for DGS/VCFS, characterized clinically by variable expressivity and reduced penetrance of cardiovascular
defects; Fgf8 gene variants may provide molecular clues to this variability.
© 2006 Elsevier Inc. All rights reserved.Keywords: Tbx1; Fgf8; 22q11 Deletion syndrome; Cardiovascular development; Genetic interaction; Pharyngeal apparatus; Pharyngeal endodermIntroduction
The transcription factor Tbx1 is required for the formation
and growth of the pharyngeal apparatus, a vertebrate-specific
structure that gives rise to components of the face, neck and
heart. Tbx1 is expressed in pharyngeal ectoderm, mesoderm,
and endoderm during development, and mutations of TBX1
have been identified in patients with DiGeorge syndrome/
VCFS (Yagi et al., 2003). The cardiovascular defects typically
seen in patients include interrupted aortic arch type B (IAA-
B), persistent truncus arteriosis (PTA), tetrology of Fallot,
ventricular septal defects (VSD), retro-esophageal right sub-
clavian artery (reRSA), right aortic arch (RAA), and pulmo-
nary atresia. In mice, haploinsufficiency of Tbx1 causes
cardiovascular defects such as IAA-B, RAA and reRSA, due
to maldevelopment of the 4th pharyngeal arch arteries⁎ Corresponding author. Fax: +1 832 825 4153.
E-mail address: fvitelli@ibt.tamhsc.edu (F. Vitelli).
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doi:10.1016/j.ydbio.2006.03.044(PAAs), while homozygous loss of Tbx1 causes PTA and
VSD (Jerome and Papaioannou, 2001; Lindsay et al., 2001;
Merscher et al., 2001). The Tbx1 requirement in 4th PAA
development is non-cell autonomous since Tbx1 is not ex-
pressed in the vessel itself (Zhang et al., 2005). Interestingly,
the 4th PAA defects in Tbx1+/− embryos are fully penetrant at
E10.5, while in term embryos, the incidence of aortic arch
defects is approximately 30%, suggesting the presence of a
Tbx1-dependent signal that triggers the recovery of 4th PAA
growth delay. We have recently demonstrated that loss of one
copy of Tbx1 in pharyngeal epithelia (endoderm and ecto-
derm) is sufficient to cause 4th PAA defects, demonstrating a
requirement of Tbx1 in one or both of these tissues (Zhang et
al., 2005).
The proper formation and maturation of the pharyngeal
apparatus require a finely orchestrated series of tissue
interactions, such that perturbation of any one of a number
of inputs may result in similar phenotypic consequences
(reviewed in Graham and Smith, 2001). For example, loss/
decreased function of genes required in neural crest cells,
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defects, since pharyngeal arch artery remodeling into the
mature aortic arch and outflow tract of the heart requires
coordinated communication between all tissue types. For
example, studies have shown that the total or partial loss of
function of several genes expressed in different tissues, such
as Raldh2 (Niederreither et al., 1999, 2001, 2002), Vegf
(Stalmans et al., 2003), Crkl (Guris et al., 2001), Fgf8 (Abu-
Issa et al., 2002; Frank et al., 2002), and Tbx1 (Jerome and
Papaioannou, 2001; Lindsay et al., 2001; Merscher et al.,
2001) can cause similar aortic arch artery patterning and
outflow tract defects. Furthermore, two recent studies have
examined the effects of genetic interaction of Crkl with
either Tbx1 and/or Fgf8 and suggest that the genes
cooperate synergistically to pattern the aortic arch in a
dose-dependent manner (Guris et al., 2006; Moon et al.,
2006). Thus, several key players required in patterning the
aortic arch have been identified, however, how these genes
interact has yet to be understood.
We had previously suggested the existence of a genetic
interaction in the endoderm between Tbx1 and Fgf8 based on
the finding that endoderm-only Fgf8 expression is down-
regulated in Tbx1-null embryos, and Tbx1+/−;Fgf8+/− com-
pound mutants showed a significant increase in arch artery
defects vs. Tbx1 haploinsufficient mice (Vitelli et al., 2002b).
Based on these data and the similarity of the cardiovascular
phenotype of Fgf8 and Tbx1 mutant mice, we speculated that
Fgf8 and Tbx1 may function in the same genetic pathway. In
order to examine this putative pathway in vivo, we took a
dual approach to test the effects of (1) forced expression of
Fgf8 in the Tbx1 expression domain and (2) deletion of Fgf8
from Tbx1-positive cells. To this end, we generated a novel
Tbx1-null allele driving the expression of the Fgf8 cDNA in
the Tbx1 domain. We have also carried out the converse ex-
periment, i.e., conditional deletion of Fgf8 in Tbx1-expressing
cells using an Fgf8flox allele (Brown et al., 2004). Overall,
results indicate that FGF8 (in excess or defect) modifies of
only one aspect of the Tbx1 cardiovascular phenotype,
namely the aortic arch patterning defects. In addition, the
use of timed deletion of Fgf8 allowed us to temporally map
the interaction of the two genes. We propose that such inter-
action is mainly relevant during the process of embryonic
recovery observed in Tbx1 heterozygous mutants.
Methods
Gene targeting and genotyping
To generate the F8KIT construct and the Tbx1Fgf8 allele, we inserted a
0.8-kb Fgf8 cDNA, encoding isoform 8b, into the XcmI site of exon 5 of
the Tbx1 gene, which encodes for a portion of the functionally essential T-
box domain. This is the same site of insertion as the previously described
LacZ knock-in reporter allele, a functionally null allele (Lindsay et al.,
2001). The Fgf8 cDNA is flanked by a 5′ IRES and a 3′ poly-adenylation
signal derived from a 300-bp fragment of the bovine growth hormone gene,
followed by a HPRT minigene for positive selection. The F8KIT construct
was linearized with SalI and electroporated into Hprt-minus AB2.2 ES
cells. HAT-resistant clones were tested for homologous recombination by
Southern blotting of HindIII-digested DNA probed with a 550-bp XcmIfragment located immediately distal to the 3′homology arm (Fig. 1A).
Approximately 8% (23/288) of the HAT-resistant colonies resulted in
the appropriately targeted allele. Of these, two ES cell lines were injected
into blastocysts by the Baylor College of Medicine Darwin Transgenic
Facility and produced 3 high-grade chimera which transmitted the mu-
tation to their offspring. Offspring was genotyped by PCR using the
following primers: F8KIT-TAR-F: taccttctgaggcggaaaga and F8KIT-TAR-R:
cctcatacaaaggccagcat.
The Fgf8+/− and Fgf8flox/flox mouse lines were supplied by Erik Meyers at
Duke University, and the Hoxa3Cre/+ line from A.M. Moon at the University of
Utah, Salt Lake City. Genotyping was performed as previously described
(Brown et al., 2004; Macatee et al., 2003; Meyers et al., 1998).Wnt1LacZ/+ mice
were obtained from A.P. McMahon.
RNA in situ hybridization and immunohistochemistry
Whole-mount and section in situ hybridization was performed as des-
cribed in (Albrecht et al., 1997). Sense and antisense RNA probes were
prepared by reverse transcription of DNA and labeled either with 35S-UTP
(Perkin Elmer) or digoxigenin (Roche). Plasmids were obtained as follows:
Tbx1 from V. Papaioannou, Fgf8 and Fgf4 from G. Martin, deletion-specific
Fgf8-probe (PstI digested cDNA) and Gbx2 from E. Meyers, Raldh2 from
K. Neiderreither, Spry4/2 from G. Minowada, Pax1 from R. Balling. At least
three embryos per genotype per stage were hybridized with each probe.
Immunohistochemistry with phosphorylated Erk1/2 (Cell Signaling) was
performed on whole-mount embryos according to the Rossant Lab Protocol
(http://www.sickkids.ca/rossant/custom/protocols.asp), subsequently embed-
ded in paraffin and sectioned at 20 μm, while immunohistochemistry
with phosphorylated histone H3 (Upstate Biotechnology), and cleaved
caspase 3 (Cell Signaling) antibodies were performed on ethanol-fixed and
paraffin-embedded E9.5–11.5 embryos serially sectioned at 8 μm. The
mitotic index was calculated by counting histone H3-positive cells/total cells
(at least 1300) for each tissue and averaging the mitotic index of 4 embryos
per genotype; P was calculated using Student's T test. LysoTracker-Red
(Molecular Probes) was used on whole mount embryos at E10.5 as
described in Vitelli et al. (2003).
Western blot analysis
Embryos at E10.5 were collected from Tbx1Fgf8/+ and wild-type crosses,
staged by somite counting and either processed whole or dissected. Crude
protein extracts were obtained from stage-matched whole embryos using iced
RIPA buffer with protein inhibitor cocktail (Roche). For the dissected embryos,
the head of each sample was discarded, and the remaining tissue was severed
between somites 20 and 21, to separate the pharyngeal region from the rest of the
embryo and the tail. These pieces were wrapped in foil, immediately frozen in
liquid nitrogen and stored at −80°C until corresponding yolk-sac genotype was
available. Three somite-matched (33 somites) samples per genotype per tissue
were pooled, and proteins were extracted as above. About 20 μg of protein
extract was run on a 12%/SDS/PAGE gel and transferred onto nylon filters.
Filters were probed with monoclonal anti-mouse Fgf8 antibody (R&D Systems)
at a 1:500 dilution in PBS/0.1% Tween overnight at 4°C, subsequently stripped
and normalized with an anti-tubulin antibody (Sigma).
Skeletal preps
We collected E18.5 Tbx1+/+, Tbx1Fgf8/+, Tbx1+/− and TbxFgf8/− embryos and
subjected them to skeletal preparations using Alcian Blue which stains
cartilage and Alizarin Red for bone as described in Hogan et al. (1994).
Tamoxifen administration
In order to activate the Tbx1mcm allele and induce Cre recombination,
we prepared a stock solution of 100 mg/ml Tamoxifen (Sigma) dissolved in
ethanol and diluted 1:10 in autoclaved sesame oil (Sigma). Vortexing for
10 min produced an emulsion suitable for IP injection. Pregnant dams were
exposed to a single dose of 75 mg/kg bodyweight of Tamoxifen at
Fig. 1. Generation and characterization of Tbx1Fgf8/+ knock-in mice. (A) Schematic of the F8KIT targeting construct and Tbx1Fgf8 allele, showing the disruption of a
portion of the T-box domain encoded by exon 5. (B) Southern blot identifying a targeted (F8) vs. WT ES cell line. (C) PCR of yolk sac DNA. (D–F) RNA in situ
hybridization with probes for Tbx1 on Tbx1+/− (D) or Fgf8 on Tbx1Fgf8/+ (E, M) or Tbx1+/− (F) embryos at E10 (D–F) and E9.5 (M). The embryo in panel E clearly
shows expression of Fgf8 in all the endogenous Fgf8 domains seen in panel F such as the fronto-nasal process (fnp) and first arch ectoderm (ec), and in the same tissues
normally expressing Tbx1 seen in panel D, including the core mesenchyme of the cranial arches (arrowheads), the secondary heart field (shf), and 3rd/4th pouches (3p,
4p). (G–I) Western blots of total protein from whole embryos (one per genotype) at E10.5 (G) or trunk and tail segments of embryos at E10.25 (H) show abundant
FGF8 production in Tbx1Fgf8/+ vs. WT samples. Purified recombinant FGF8b (250 ng) protein was loaded as a control. Panel I shows how the embryos were dissected
to generate panel H. (J–K) Sagittal sections through E9.5 WT (J) and Tbx1Fgf8/+ (K) embryos processed for phospho-histone H3 assay showing representative regions
of 1st and 2nd arch mesenchyme in which positive cells were counted. (L) Xgal stained stage-matchedWnt1LacZ/+ embryo shows high NCC density in the 1st and 2nd
pharyngeal arches (I, II). (N) Summary of phosphorylated histone H3 assay in Tbx1Fgf8/+ at E9.5 (23 somites). A significant increase in proliferation of the pharyngeal
arch mesenchyme (P = 0.04) was seen as compared to other target regions of the embryo (endoderm and splanchnic mesenchyme/secondary heart field), or control
regions in which Tbx1-driven Fgf8 is not expressed (neural tube).
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a vaginal plug was observed.
Results
Generation of the Fgf8 knock-in allele at the Tbx1 locus
In order to test the effect of FGF8 released by Tbx1-
expressing cells, we generated a Tbx1-driven Fgf8 knock-in
allele, Tbx1Fgf8 (Fig. 1A–C). We have previously utilized this
same site of insertion to generate our Tbx1LacZ reporter allele,which reproduces endogenous Tbx1 expression and is a
functionally null allele (Lindsay et al., 2001). Thus, by knocking
in the F8KIT targeting construct, we expected to simultaneously
inactivate Tbx1 and drive Fgf8-cDNA expression by Tbx1
regulatory elements. Using an appropriately targeted ES cell
line, we were able to generate chimera which transmitted the
Tbx1Fgf8 allele to their offspring. Tbx1Fgf8/+ mice were
apparently healthy and fertile but exhibited an abnormally
coiled tail, which required amputation (see below). To test
whether the Fgf8 cDNA is expressed properly, we
performed RNA in situ hybridization on embryos at E10
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Results showed robust expression of Fgf8 mRNA in all of
the domains where Tbx1 is expressed, including the core
mesenchyme of the arches, the pouch endoderm of arches
3–6 and the secondary heart field (Fig. 1D–F). In Tbx1Fgf8/+
embryos, the endogenous Fgf8 domains are also clearly
visible (Fig. 1E). To test whether the Fgf8-transgene mRNA
is translated, we extracted proteins from whole or segments
of Tbx1Fgf8/+ embryos and subjected them to Western blot
analysis using a monoclonal Fgf8 antibody. We found an
abundant increase in levels of FGF8 protein in Tbx1Fgf8/+
vs. wild-type total protein extracts from embryos at E10.5
(38 somites, Fig. 1G). Since Fgf8 mRNA from the transgene
is ectopically and abundantly expressed in the somites (see
below), we wished to test whether the Tbx1Fgf8 allele
produced detectable FGF8 in the pharyngeal region alone.
We therefore separated trunk and tail regions of the embryos
(shown in Fig. 1I) and extracted total protein from a pool of
3 stage matched trunks or tails for each genotype. The trunk
region included the heart and the area of tissue surrounding
the pharyngeal apparatus, while the tail region included all
the structures caudal to the forelimb bud. We performed
Western blots of trunk and tail segments and found
abundant FGF8 protein in both fractions (Fig. 1H).
The Fgf8 knock-in modulates levels of cellular proliferation in
the pharyngeal arch mesenchyme
Since partial loss of function of Fgf8 causes a decrease in
cell survival (Abu-Issa et al., 2002; Frank et al., 2002) and
Tbx1 conditional mutants show decreased levels of cellular
proliferation (Xu et al., 2004, 2005), we tested cell survival
and proliferation in the presence of the Fgf8 transgene.
Immunohistochemistry with cleaved caspase 3 (E9.5) or
LysoTracker analysis (E10.5) showed no significant differ-
ences in apoptosis between 3 pairs of stage matched Tbx1Fgf8/
+ and WT embryos (not shown). Proliferation levels were
assayed by counting phosphorylated histone H3-labeled cells
in the pharyngeal endoderm, pharyngeal arch mesenchyme,
splanchnic mesoderm of the secondary heart field region, and
neural tube in 4 stage-matched Tbx1Fgf8/+ and WT embryos at
E9.5. Although proliferation seemed slightly altered in all of
the Tbx1Fgf8/+ tissues examined, we detected statistically
significant increase in proliferation only in the pharyngeal arch
mesenchyme of Tbx1Fgf8/+ embryos (P = 0.04, Figs. 1J, K, N).
Neural crest-derived cells (NCC) should represent the
majority of arch mesenchymal cells at this stage. To test
this, we generated stage-matched Wnt1LacZ/+ embryos and
stained with Xgal to reveal Wnt1-positive cells. Sections
demonstrate that the cranial arch mesenchyme analyzed in the
proliferation assay is densely populated by cells of NC origin
(blue cells in Fig. 1L). We speculate that ectopic FGF8
produced by Tbx1-expressing cells from the Tbx1Fgf8 allele
(Fig. 1M) may exert a non-cell autonomous effect on NCC
proliferation.
Since it has been shown that Fgf4 and Fgf8 have redundant
roles in limb development (Lu et al., 2006), we tested whetherFgf4 expression is changed in Tbx1Fgf8/+ embryos. Distri-
bution of Fgf4 transcripts assayed by RNA in situ
hybridization at E10 was apparently normal in Tbx1Fgf8/+
embryos (data not shown).
Tbx1Fgf8/+ mice exhibit axial skeletal abnormalities
All Tbx1Fgf8/+ animals (n = 55) presented with moderate
to severe tail kinking or coiling (Fig. 2A–C). In the most
severe cases, the abnormal tail required perinatal amputation
as the coil formed a tight, ventrally located knot which in-
terfered with mating and excretion of waste. Skeletal pre-
parations at E18.5, revealed that the lumbar and sacral
regions of the spine were affected in addition to the caudal
region (Fig. 2D–I). The ventral aspect of each affected ske-
letal element appeared fused to the adjacent elements, for-
ming a rigid, curved structure, which induced kyphosis and
greatly reduced flexibility in the adult animal. The number
of fused elements was proportional to the severity of the
tail coiling. Normally, the caudal portion of the skeleton is
not ossified at E18.5, and the anterior and posterior por-
tions of adjacent vertebral units should be well separated
and flank the nucleus polposus. In Tbx1Fgf8/+ mutants, the
anterior and posterior portions of the original sclerotomal
element failed to separate fully and appeared fused on the
ventral aspect of the tail, resulting in a cup-like structure
around the nucleus polposus (Fig. 2I). RNA in situ hybrid-
ization showed high Tbx1-driven Fgf8 mRNA levels in the
ventral sclerotome at E11.5, where endogenous Fgf8 is not
expressed (Fig. 2J–L).
In addition, all Tbx1Fgf8/+ embryos showed abnormal
anterior arches of the atlas and the axis, the first and second
cervical vertebrae, respectively, compared to WT and Tbx1+/−
embryos (Fig. 2M–O). The C2 vertebral body was missing in
all mutants analyzed (n = 23), while the centrum of C1 was
either absent (n = 9) or severely hypoplastic (n = 14).
Surprisingly, similar defects have been described in homozy-
gous Tbx1−/− and Chrd−/− mutants, which both show decreased
Fgf8 expression in the pharyngeal region (Bachiller et al., 2003;
Jerome and Papaioannou, 2001). However, all of the remaining
skeletal elements that are defective in Tbx1−/− embryos formed
normally in Tbx1Fgf8/+ mutants, including the middle ear
ossicles and tympanic ring, the bones of the jaw and the palatine
shelves (not shown).
Endogenous Fgf8 is first expressed in a caudal-to-rostral
gradient peaking at the distal tail-bud where it is
antagonized by an opposing Raldh2-dependent retinoic acid
gradient, such that the interface of the two gradients defines
the position of the determination front where the somites
form (Dubrulle and Pourquie, 2004; Niederreither et al.,
2003). Normal Raldh2 expression in the Tbx1Fgf8/+ mutants
suggests that disruption of this gradient is not the mecha-
nism of axial defects in these mice. Furthermore, the ex-
pression of Pax1, BMP4, Fgf4 and levels of phosphorylated
Erk1/2 protein appeared normal in mutants at E10, suggest-
ing that somite patterning and FGF signaling are initially
normal (not shown).
Fig. 2. The skeletal phenotype of Tbx1Fgf8/mice. Mild (A) to severe (B) tail kinking was seen in all Tbx1Fgf8/+mutants born and was evident at E18.5 (C). Skeletal preps
at E18.5 showed fusion of caudal vertebral bodies (arrows in G and I) surrounding the nucleus pulposus (NP) in the mutants compared toWTcontrols (D–I) most likely
caused by ectopic expression of Fgf8 in the ventral sclerotome, as seen by in situ hybridization with a Fgf8 RNA probe on Tbx1Fgf8/+ vs. WTembryos at E11.5 with 45
somite pairs (N, O, respectively; cranial is up, and dorsal is right). Tbx1 expression is detectable in this domain by X-gal staining of Tbx1LacZ/+ embryo at E11.5 (M). (J–
L) The cranial portion of the axial skeleton was also abnormal in Tbx1Fgf8/+, manifesting as severe hypoplasia of the anterior arch of the atlas (arrow in L) compared to
both WT (J) and Tbx1+/− (K) embryos at E18.5.
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We examined the progeny derived from Tbx1Fgf8/+ and
wild-type crosses at embryonic day E18.5 and at weaning
(post-natal day (P) 21). The expected number of Tbx1Fgf8/+
fetuses was recovered at E18.5 (56% Tbx1Fgf8/+ vs. 44%
wild type). In contrast, at weaning, we observed the loss
of 10.5% of Tbx1Fgf8/+ (77 observed vs. 86 expected,
n = 172). This loss is more than twice what we observed in
similar mixed C57/129 background for Tbx1+/− mice at
weaning (4.1%, 139 Tbx1+/− vs. 145 expected, n = 290),
suggesting that forced expression of Fgf8 exacerbates the Tbx1
haploinsufficiency phenotype. Intercrosses between Tbx1Fgf8/+
mice yielded no homozygous Tbx1Fgf8/Fgf8 at weaning. When
collected at E18.5, we recovered the appropriate proportion ofTbx1Fgf8/Fgf8 (10/41; 24%); all homozygous mutants show PTA,
indistinguishable from that observed in Tbx1−/− embryos (Fig.
3C, F; see below).
In order to determine if the forced expression of Fgf8 can
modulate the Tbx1-mutant phenotype, we examined
Tbx1Fgf8/+ and Tbx1Fgf8/Fgf8 embryos at E10.5 and 18.5.
At E18.5, the heart defects observed in Tbx1Fgf8/+, and
Tbx1Fgf8/− or Tbx1Fgf8/Fgf8 were identical to those seen in
Tbx1+/− and Tbx1−/−, respectively (Fig. 3A–L). Specifically,
we observed retroflex right aortic arch, cervical aortic arch,
cervical or retro-esophageal right subclavian artery in 75% of
Tbx1Fgf8/+ mutants (Table 1). Interestingly, the incidence of
cardiovascular defects in Tbx1Fgf8/+ was approximately twice
the incidence of the defects caused solely by Tbx1
haploinsufficiency (75% vs. 35%, respectively; n = 114,
Table 1
Frequency of aortic arch defects in Tbx1Fgf8/+ at E18.5
Genotype Normal Abnormal
Tbx1+/+ 44 0
Tbx1+/− 19 7 (35%)
Tbx1Fgf8/+ 11 33 (75%)
Defects are twice more frequent in Tbx1Fgf8/+ compared to Tbx1+/− (P = 0.0008).
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weaning. In all the Tbx1Fgf8/Fgf8 or Tbx1Fgf8/− fetuses
examined (n = 13), we observed persistent truncus arteriosis
(PTA) associated with right (n = 6) or left (n = 16) aortic
arch, and in only one case did we observe double aortic arch
with aortic dilation (n = 1) (Fig. 5F). In all mutants, the PTA
communicated solely with the right ventricle, the truncal
valve had lost continuity with the mitral valve, and there was
a ventricular septal defect (VSD) (Fig. 5F–H), as seen in
Tbx1−/− embryos (Jerome and Papaioannou, 2001; Lindsay et
al., 2001; Vitelli et al., 2002a). We did not observe
intracardiac defects in Tbx1Fgf8/+.Fig. 3. Normal cardiovascular development is not restored by the Tbx1Fgf8 allele. (A–I
branching of the right subclavian artery (arrows in D, E compared to RSA in A, W
haploinsufficient control embryos (B). Tbx1Fgf8/− (C) or Tbx1Fgf8/Fgf8 (F) show per
between mitral and semilunar valves (compare arrowhead in G, WT to H–I, Tbx1Fgf8/
(arrow in J) or abnormal pharynx lacking caudal arches and arch arteries in Tbx1Fgf8/−
left subclavian arteries, Ao, aorta; PT, pulmonary trunk; RV, LV, LA, right or left ventr
arches.Consistent with the phenotype observed at E18.5,
histological sections at E10.5 revealed hypoplasia of the
4th pharyngeal arch arteries in Tbx1Fgf8/+ and hypoplasia of
the caudal pharyngeal apparatus in Tbx1Fgf8/Fgf8 embryos) Tbx1Fgf8/+ embryos at E18.5 (D-E) show interrupted aortic arch (IAA), aberrant
T) and cervical aortic arch (arrowhead in E) similar to the phenotype in Tbx1
sistent truncus arteriosis (PTA) associated with VSD (I) and loss of continuity
Fgf8). (J–L) At E10.5, sagittal sections of Tbx1Fgf8/+ show a hypoplastic 4th PAA
embryos (K–L); rcc, lcc, right and left common carotid arteries; rsa, lsa, right and
icle or atrium; AS, aortic sac; dAo, dorsal aorta; I, II, first and second pharyngeal
Fig. 4. Timed, tissue-specific loss of Fgf8. RNA in situ hybridization with a
deletion-specific probe that does not detect the recombined Fgf8flox allele reveals
differential loss of Fgf8 in the pharyngeal epithelia of Tbx1mcm/+;Fgf8fl/− (B, D,
F) as compared to control Tbx1mcm/+;Fgf8fl/+ (A, C, E) depending on the timing
of deletion induction. Embryo stage and stage of Tamoxifen (TM) exposure is
shown adjacent to each set of panels. (A–B) Injection at E7.5 does not cause
reduced expression of Fgf8 in the pharyngeal ectoderm (arrows) while the
endoderm expression appeared patchy in Tbx1mcm/+;Fgf8fl/− embryos at E9.5.
(C–D) When TM is injected at E8.5, expression is reduced in the caudal
ectoderm and lost in the endoderm, while other regions continue to express Fgf8
robustly (i.e., isthmus, is). (E–F) In embryos at E10.25 exposed to TM at E9.5
caudal endoderm expression of Fgf8 is weak in control embryos (E) and absent
in Tbx1mcm/+;Fgf8fl/− mutants, while the ectoderm expression is strong in both
mutant and control embryos.
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respectively.
The thymic, palate and external ear abnormalities character-
istic of Tbx1 mutants were not modified by the presence of the
Fgf8 knock-in allele (data not shown) Thus, Fgf8 expression in
the Tbx1 expression domain enhances the aortic arch phenotype
of Tbx1 mutants but does not affect other associated
abnormalities.
Forced Fgf8 expression in the Tbx1 domain is not sufficient to
cause aortic arch abnormalities
To establish whether ectopic Fgf8 expression per se confers
aortic arch abnormalities, we crossed Tbx1Fgf8/+ to Dp1/+ mice,
which harbor a duplication carrying two functional copies of
Tbx1 (Lindsay et al., 1999). All of the Dp1/Tbx1Fgf8 embryos at
E18.5 examined (n = 18; see Table 2) had normal aortic arch
patterning and thymus size indicating that the aortic arch
phenotype observed in Tbx1Fgf8/+ animals is due to Tbx1
haploinsufficiency and that the expression of Fgf8 in the Tbx1
domain alone is not sufficient to cause those abnormalities.
Conversely, skeletal abnormalities associated with the Tbx1Fgf8
allele were not rescued by the duplication, indicating that this is a
gain-of-function phenotype.
Inactivation of Fgf8 in Tbx1-expressing cells
To address if Tbx1-expressing cells are an essential
source of FGF8 during cardiovascular development and to
establish when in embryogenesis such expression may be
required, we used a Tamoxifen-inducible Tbx1-driven Cre
allele, Tbx1mcm, to delete the Fgf8flox conditional allele from
Tbx1-positive cells. If Tbx1 activates expression of Fgf8, we
expect Tbx1mcm/+;Fgf8fl/− embryos to enhance the Tbx1+/−
phenotype, since Tbx1mcm is a functionally null allele (Xu et
al., 2004). Hence, we crossed Tbx1mcm/+;Fgf8+/− mice to
Fgf8fl/+ or Fgf8fl/fl mice and subsequently exposed pregnant
dams to a single dose of Tamoxifen (75 mg/kg body
weight) at either E7.5, 8.5, or 9.5. Embryos were harvested
at E9.5, E10.5, and E18.5. Once Tamoxifen is cleared, no
further Cre-mediated deletion will occur, although the Tbx1
locus may remain transcriptionally active (the half-life of
Tamoxifen is 11.9 h (Robinson et al., 1991).
In order to confirm tissue specific loss of Fgf8 in Tbx1-
positive cells, we performed RNA in situ hybridizationTable 2




Tbx1Fgf8/+ 11 9 (45%)
Dp1/ Tbx1Fgf8/+ 18 0
Normal aortic arch patterning is restored in the presence of the Dp1 allele
carrying two functional copies of Tbx1, suggesting that the phenotype of
Tbx1Fgf8/+ mutants is attributable to an aggravating effect of excess Fgf8 in the
context of Tbx1 haploinsufficiency.using an Fgf8 exon 4–5 specific probe (Brown et al., 2004).
We tested E9.5 or E10.25 embryos exposed to Tamoxifen at
E7.5, E8.5 or E9.5. In compound Tbx1mcm/+;Fgf8fl/−
embryos injected at E7.5, expression of Fgf8 mRNA was
irregular in the pharyngeal endoderm and persisted in the
ectoderm, as compared to Tbx1mcm/+;Fgf8fl/+ control embry-
os (Fig. 4A–B), indicating that the deletion is inefficient at
this stage of induction. In Tbx1mcm/+;Fgf8fl/− mutants
exposed to Tamoxifen at E8.5, the endodermal expression
of Fgf8 decreased to barely detectable levels, yet persisted
in the caudal ectoderm covering the arches (Figs. 4C–D).
Control embryos injected at E9.5 and collected at E10.25
showed low but evident levels of Fgf8 expression within
Table 3
Frequency of aortic arch defects at E18.5 after timed ablation of Fgf8 in the
Tbx1 domain
Genotype E7.5 E8.5 E9.5
Abnormal/Total
Tbx1mcm/+; Fgf8+/+ 16/41 (39%)*,^
Tbx1mcm/+; Fgf8+/− 29/37 (78%)*
Tbx1mcm/+; Fgf8flox/+ 16/31 (52%) 10/31 (32%) 19/31 (63%)^
Tbx1mcm/+; Fgf8flox/− 21/26 (81%) 28/32 (88%) 33/37 (89%)
Comparison of Tbx1mcm/+; Fgf8+/+ and Tbx1mcm/+; Fgf8+/− reconfirmed that
Tbx1 and Fgf8 interact in vivo as the frequency of defects increases
significantly in Tbx1mcm/+; Fgf8+/− embryos (*P = 0.006). Tbx1-driven
deletion of one copy of Fgf8 in Tbx1mcm/+; Fgf8flox/+ embryos exposed to
TM at E9.5 is sufficient to recapitulate the effect of germ-line ablation of
Fgf8, since the frequency of defects in E9.5 induced Tbx1mcm/+; Fgf8flox/+
embryos is significantly greater that in Tbx1mcm/+; Fgf8+/+ (^P = 0.04) and
closely approached the frequency seen in Tbx1mcm/+; Fgf8+/− (78% vs. 63%;
P = 0.2).
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the ectoderm and cranial pouches (Fig. 4E). In Tbx1mcm/+;
Fgf8fl/− littermates, although signal persisted in the cranial
pouches, no Fgf8 expression was detectable in the caudal
pouch endoderm (Fig. 4F), consistent with efficiency of
Tbx1mcm-mediated recombination at this stage of TamoxifenFig. 5. (A–B) Hoxa3-driven ablation of Tbx1 causes OFT defects. Comparison of Tb
that is associated either with right sided retroflex aortic arch (RAA) or left aortic arch (
summarizes the data presented here and elsewhere regarding the requirements of Fgf8
location of the Tbx1/Fgf8 interaction (green). Fgf8 is required in the ectoderm (Macate
line). Tbx1 is required after E7.5 and before E9 (Xu et al., 2005) in the pharyngeal ect
domain affected only the 4th PAA haploinsufficiency phenotype, and analysis of th
important at least after E9.5, yet it may also occur earlier (dashed line). Thus, we s
required for embryonic recovery from 4th PAA hypoplasia (asterisk).exposure (Xu et al., 2005). In all the embryos tested, the
Fgf8 signal remained strong in the regions of the embryo
that do not express Tbx1, such as the isthmus, first arch
ectoderm (Figs. 4C–D) and the apical ectodermal ridge (not
shown).
Fgf8 dosage reduction in Tbx1-expressing cells is sufficient to
enhance the Tbx1 haploinsufficiency phenotype
We next sought to address the effect of timed ablation of
Fgf8 in the Tbx1 domain. The conditional deletion of a single
copy of Fgf8 in Tbx1mcm/+; Fgf8fl/+ compound mutants at E18.5
exposed to Tamoxifen at E9.5 caused a significant increase in
the penetrance of aortic arch defects compared to Tbx1mcm/+;
Fgf8+/+ embryos (Table 3; 63% vs. 37%, P = 0.04). The
penetrance of these defects in E18.5 Tbx1mcm/+;Fgf8fl/+ (TM
E9.5) embryos is statistically not different from that observed in
Tbx1mcm/+;Fgf8+/− animals (63% vs. 78%, P = 0.2). Thus,
conditional deletion of one Fgf8 copy in Tbx1 expressing
cells at E9.5 has similar phenotypic consequences as the
germ line knockout of one Fgf8 allele. On the other hand,
deletion of Fgf8 with TM at E7.5 and E8.5 did not result in
phenotypic enhancement. This may be due to inefficient
deletion of Fgf8 in the critical domains at these time pointsx1−/− (A) and Hoxa3Cre/+;Tbx1fl/− (B) embryos at E18.5 reveals an identical PTA
LAA). (C) Proposed tissue and time map of Tbx1-Fgf8 interaction. This diagram
(blue) and of Tbx1 (red) in arch artery development, and the potential timing and
e et al., 2003), but the developmental time point has not been established (dashed
oderm and/or endoderm (Zhang et al., 2005). Forced Fgf8 expression in the Tbx1
e timed conditional deletion mutants showed that the Tbx1/Fgf8 interaction is
peculate that the Tbx1/Fgf8 interaction probably occurs in the endoderm and is
567F. Vitelli et al. / Developmental Biology 295 (2006) 559–570or to a non-requirement for Fgf8 in Tbx1-positive cells at
these stages.
Further reduction of Fgf8 dosage in Tbx1mcm/+;Fgf8fl/−
animals exposed to Tamoxifen at E9.5 increased the percentage
of abnormal animals to 89% (n = 37), but the change was not
statistically significant when compared to the penetrance in
Tbx1mcm/+;Fgf8fl/+ animals (89% vs. 63%, P = 0.2). Further-
more, we did not identify any additional phenotypic abnormal-
ity in Tbx1mcm/+;Fgf8fl/− compared to Tbx1mcm/+;Fgf8+/+
animals. In particular, we did not find outflow tract defects in
these mutants (Table 2).
These data, while indicating that Tbx1-expressing cells are a
critical source of FGF8 at or after E9.5 for the Tbx1-Fgf8
interaction, also suggest that under the conditions tested, the
phenotypic significance of this interaction is limited to the
development of the 4th PAAs.
Fgf8 and Tbx1 are required in different tissues or stages in
OFT morphogenesis
Fgf8 is crucial for outflow tract development (Abu-Issa et
al., 2002; Frank et al., 2002; Hu et al., 2004; Macatee et al.,
2003), and the results shown above suggest that Tbx1-
expressing cells are not a critical source of FGF8 for that
developmental role. Thus, it is yet to be determined at what
developmental stage and in which tissue Fgf8 is required for
outflow tract development. It has been previously shown
that Hoxa3Cre-driven ablation of Fgf8 causes aortic arch
defects but not outflow tract defects (Macatee et al., 2003).
Deletion of one copy of Tbx1 using the same Cre-driver,
which is active in the pharyngeal ectoderm from E8.25 (10
somites) and endoderm from E8.5 (12 somites), is sufficient
to cause aortic arch defects (Zhang et al., 2005), but the
homozygous deletion of Tbx1 in the Hoxa3 domain has not
been tested. Therefore, we obtained Hoxa3Cre/+;Tbx1flox/−
embryos at E18.5 and examined their outflow tract
phenotype. Embryos exhibited PTA, which is also seen in
Tbx1−/− animals (Figs. 5A–B). Thus, expression of Tbx1,
but not of Fgf8, in the Hoxa3 domain is crucial for outflow
tract development. These data, together with the finding that
outflow tract development is unaffected in Tbx1mcm/+;
Fgf8flox/− vs. Tbx1mcm/+;Fgf8flox/− and Tbx1Fgf8/Fgf8 vs.
Tbx1−/− mutants, suggest that Tbx1 and Fgf8 are required
at different developmental times or in different tissues for
outflow tract development.
Discussion
Axial skeletal defects in Tbx1Fgf8/+ mutants
Wild-type expression levels of Raldh2, Pax1, BMP4, Fgf4
and levels of phosphorylated Erk1/2 protein in Tbx1Fgf8/+
mutants at E10 suggests that somite patterning and FGF
signaling is initiates normally in these mice. However, the
hypoplasia of the anterior arches of the first two cervical
vertebrae and the fusion of lumbar, sacral, and caudal vertebral
bodies suggest that Fgf8 expression from the Tbx1Fgf8 alleleperturbs a later developmental process. Furthermore, the
different phenotypes seen in the cranial and caudal vertebral
elements suggest that skeletal precursors may respond differ-
ently to misexpression of Fgf8 depending on their cranial-to-
caudal position. Further studies are required to understand
which regulatory network is disrupted in the axial skeleton of
these mice.
The Tbx1Fgf8 allele enhances the Tbx1 haploinsufficiency
phenotype
Expression analysis at the RNA and protein levels demon-
strated that the Fgf8 cDNA knocked into the Tbx1 locus is
robustly transcribed and translated. Proliferation levels of the
pharyngeal arch mesenchyme increased significantly in re-
sponse to Tbx1-driven Fgf8 expression. However, in contrast to
our hypothesis,Fgf8 expressed by the Tbx1-positive cells did not
rescue any of the phenotypic abnormalities of Tbx1 mutants.
Conversely, we observed an increase in aortic arch defects in
Tbx1Fgf8/+ mice, indicating that additional Fgf8 expression in
these cells, in the context of Tbx1 haploinsufficiency, can worsen
the aortic arch phenotype caused by loss of one copy of Tbx1.
Conditional ablation of Fgf8 in Tbx1 expressing cells also
enhanced the haploinsufficiency phenotype. Thus, although our
data support that at least one critical source of FGF8 for aortic
arch patterning resides within Tbx1-expressing cells, the effect
of forced Fgf8 expression in these cells is also detrimental. The
latter finding may result from an Fgf8 dosage effect. The
Tbx1Fgf8 allele may produce an excess of Fgf8, which may
overcompensate the loss of Tbx1 function, thus phenocopying
the 4th PAA defects see in TBX1 overexpressing animals (Liao et
al., 2004). However, we found that per se, overexpression of
Fgf8 does not cause aortic arch defects since increasing the Tbx1
dosage by introducing the Dp1 allele suppresses the Tbx1Fgf8
aortic arch phenotype rather than enhancing it. Thus, it appears
that Tbx1-driven Fgf8 expression can exert its phenotypic effect
only on a faulty 4th PAA, and that haploinsufficiency of Tbx1 is a
prerequisite to uncovering sensitivity of the 4th PAA to
increased dosage of Fgf8 in the Tbx1 domain.
Dosage sensitivity to Fgf8 has been well documented in the
development of several organs including the cardiovascular
system (Abu-Issa et al., 2002; Frank et al., 2002), salivary
glands (Jaskoll et al., 2004), and forebrain (Storm et al., 2003).
Recently, Waldo et al. (2005) speculated that an observed
increase in proliferation of splanchnic mesenchymal cells in the
cardiac neural crest-ablated chick is due to excessive FGF8 and/
or FGF4 signaling in the pharyngeal arches, which contributed
to arch artery and outflow tract defects in this model (Waldo et
al., 2005). These data provide further support for the hypothesis
that either too much or too little FGF can be detrimental, and
that Fgf8 levels must be finely titrated for normal cardiovascular
development to progress.
Time and spatial resolution of the Fgf8-Tbx1 interaction in vivo
In vitro studies can test the transactivation of a target gene by
a transcription factor. However, this is an oversimplification of
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data show that in the context of Tbx1 haploinsufficiency, the
timed conditional deletion of one Fgf8 copy in Tbx1 expressing
cells at E9.5 has similar phenotypic consequences on
cardiovascular development as the germ line knockout of one
Fgf8 allele. However, homozygous loss of Fgf8 in these cells at
E9.5 does not significantly aggravate the phenotype, although
the incidence does rise to 89%. The lack of statistical
significance may be attributable to near saturation of the
experimental system, since the frequency of defects in double
germ line heterozygous Tbx1+/−;Fgf8+/− embryos is already
78%. Alternatively, the 4th PAA may have a threshold of
tolerance to decreased Fgf8 to which it responds. Indeed, a
dose-dependent but non-linear epistatic response to variations
of Fgf8 levels has been reported during embryonic subman-
dibular salivary gland development, providing the precedent for
a threshold-like response to Fgf8 signaling (Jaskoll et al., 2004).
In addition, since Fgf8 encodes a diffusable molecule and
Tbx1mcm-induced recombination may not be highly efficient,
adjacent non-deleted cells may supply compensatory FGF8 to
their neighbors.
Published data suggest that the primary role of Fgf8 in 4th
PAA development occurs in the ectoderm (Macatee et al.,
2003). Data from the timed deletion of Tbx1 using an ubiquitous
inducible Cre driver suggest that the critical time point for Tbx1
in 4th PAA development occurs around E7.5–8.5 (Xu et al.,
2005). In this study, our data suggest that the Tbx1-Fgf8
interaction in 4th PAA growth occurs after E9.5. Thus, Fgf8 and
Tbx1 do act to modify PAA development, yet this interaction
does not occur at the time point at which Tbx1 is essential
(E7.5–8.5), nor in the tissues where Fgf8 is required (ectoderm)
since Tbx1mcm does not induce recombination in the ectoderm at
this stage (Xu et al., 2005). Thus, Tbx1 and Fgf8 most likely
have separate primary roles in supporting 4th PAA formation.
We speculate that, instead of interacting with Tbx1 during its
primary role in artery formation, Fgf8 modifies the 4th PAA
recovery from arterial growth delay, a phenomenon observed in
Tbx1 haploinsufficient mutants after E10.5 (Lindsay and
Baldini, 2001). Our data suggest that the endoderm is the
most probable source of Fgf8 exerting this later, “secondary”
function on 4th PAA development, and is therefore the likely
site of the Tbx1-Fgf8 interaction. These hypotheses are
summarized in Fig. 5C.
Our hypotheses are consistent with recent evidence of
genetic interaction between Tbx1 and Crkl (Guris et al., 2006).
Crkl encodes an adaptor protein required in the FGF signal
transduction pathway (Larsson et al., 1999) and is highly
abundant in the neural crest derivatives and in the pharyngeal
apparatus (Guris et al., 2001). While Crkl haploinsufficiency
has no consequences for cardiovascular development, double
heterozygous Crkl+/−;Tbx1+/− embryos between E16.5-P2
showed increased expressivity and penetrance of congenital
heart defects compared to Tbx1+/− embryos (Guris et al., 2006).
Over 97% of Crkl+/−;Tbx1+/− compound heterozygotes had
aortic arch abnormalities compared to 33% for Tbx1+/−, while at
E10.5 the frequency of defective 4th PAAs was similar in both
genotypes (Guris et al., 2006). Although it is not clear whetherthe 4th PAAs fail to form altogether in Crkl+/−;Tbx1+/−mutants,
the data suggest that Crkl haploinsufficiency severely impairs
the Tbx1-dependent embryonic recovery from 4th PAA
hypoplasia, implicating a role for FGF signaling in this process.
The Tbx1-Fgf8 interaction is relevant to aortic arch but not
outflow tract development
Overall, our data support a strong genetic interaction in aortic
arch development but do not provide evidence that this
interaction is relevant to OFT development. The OFT
phenotype due to complete Tbx1 loss of function was
unchanged in Tbx1Fgf8/Fgf8 vs. Tbx1−/− mutants suggesting
that the function of Tbx1 in OFT development is not mediated by
Fgf8, and that the Fgf8 role in OFT development is not Tbx1-
dependent. These data are also consistent with the fact that we do
not observe a change in cell proliferation levels in the secondary
heart field of Tbx1Fgf8/+ mutants, while Tbx1 loss of function
mutants show reduced cell proliferation in this region (Xu et al.,
2004). In addition, data from the Hoxa3Cre/+;Tbx1flox/− mutants
suggest that the critical sources for Tbx1 and Fgf8 are regionally
and/or temporally distinct.
Fgf8 deletion with a transgenic Tbx1-Cre driver in Tbx1-
Cre∷Fgf8flox/− mice was shown to be associated with OFT
defects, including PTA, double outlet right ventricle, transpo-
sition of the great arteries and Tetrology of Fallot (Brown et al.,
2004). This discrepancy with the present study may be
attributed to a more robust expression of the Cre in the
transgenic line as compared to Tbx1mcm/+. Alternately, the
transgenic Tbx1-Cre may show ectopic expression domains, for
example at the level of the cardiac crescent and myotome
(Brown et al., 2004), where endogenous Tbx1 is not expressed
(Jerome and Papaioannou, 2001). The generation of a
constitutively active Cre driver under the control of endogenous
regulatory elements may provide further clarification of the
observed phenotypic differences. Hu et al. have proposed that
the essential Tbx1-Fgf8 interaction occurs in the OFT, based on
the OFT-specific suppression of a transgene harboring a Tbx1-
dependent Fgf8 enhancer in a Tbx1-deficient background (Hu et
al., 2004). However, since the disruption of the 5 putative TBEs
singly did not affect transgene expression in vivo, nor did
mutation of up to 3 consensus sites in tandem, conclusive in
vivo evidence of the significance of this Fgf8 enhancer has not
been provided. In addition, Hoxa3Cre-driven deletion of Fgf8
does not cause OFT defects (Macatee et al., 2003), whereas we
have shown in this study that ablation of Tbx1 by the same
driver causes PTA. Although a mounting body of evidence has
made it clear that both Tbx1 and Fgf8 are required for OFT
development (Abu-Issa et al., 2002; Farrell et al., 2001; Frank et
al., 2002; Jerome and Papaioannou, 2001; Lindsay et al., 2001;
Macatee et al., 2003; Vitelli et al., 2002a; Waldo et al., 2005; Xu
et al., 2004, 2005), our data imply that the Fgf8-Tbx1 interaction
is not essential for OFT development.
Although it is still possible that Tbx1 has direct transcrip-
tional activity on the Fgf8 gene in the endoderm, our in vivo
data are more supportive of a complex picture in which the two
genes do not interact directly, neither at the time point nor in the
569F. Vitelli et al. / Developmental Biology 295 (2006) 559–570location of their primary individual roles in 4th PAA
development. On the other hand, it is possible that the
interaction concerns the signal transduction pathway rather
than the expression of the ligand. Alternatively (or in addition),
each gene functions in pathways that independently affect the
same structure.
Overall, our genetic data confirm that the Tbx1-Fgf8
interaction is critical for 4th arch artery development, suggest-
ing that such interaction is not relevant for other aspects of the
Tbx1 mutant phenotype, and that it occurs mostly in the
pharyngeal endoderm at mid-gestation. We propose that the
interaction is essential for the embryonic recovery from arterial
growth delay previously described in Tbx1 haploinsufficient
mice. This finding is clinically relevant to 22q11 Deletion
Syndrome since the Fgf8 dosage sensitivity of the 4th PAA in
the context of Tbx1 haploinsufficiency may provide possible
grounds for the variable penetrance of aortic arch defects seen in
del22q11 patients. Further understanding the mechanism of the
Tbx1-Fgf8 interaction in the endoderm may uncover an entry
point for altering clinical severity of del22q11-associated aortic
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